GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Total Current Liabilities

Chimeric Therapeutics (ASX:CHM) Total Current Liabilities : A$10.19 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Chimeric Therapeutics's total current liabilities for the quarter that ended in Dec. 2023 was A$10.19

Chimeric Therapeutics Total Current Liabilities Historical Data

The historical data trend for Chimeric Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Total Current Liabilities Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Total Current Liabilities
7.36 9.02 14.69

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Liabilities Get a 7-Day Free Trial 8.60 9.02 6.41 14.69 10.19

Chimeric Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Chimeric Therapeutics's Total Current Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.813+0
+Other Current Liabilities+Current Deferred Liabilities
=3.88+0
=14.69

Chimeric Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=6.719+0
+Other Current Liabilities+Current Deferred Liabilities
=3.473+0
=10.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Chimeric Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Total Current Liabilities
Comparable Companies
ASX:TRP ASX:VBS ASX:IMC ASX:PAB ASX:ATX ASX:KZA ASX:ATH ASX:IXC ASX:BGT ASX:ACR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CHMMF:USA
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Website
https://www.chimerictherapeutics.com
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines